CAMURUS
Camurus is a research based pharmaceutical company with a firm commitment to the development and commercialization of innovative specialty medicines, providing patients suffering from serious and chronic disease, with better treatment outcomes and quality of life.
CAMURUS
Industry:
Health Care Medical Pharmaceutical
Founded:
1991-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.camurus.com
Total Employee:
11+
Status:
Active
Contact:
+46462865730
Total Funding:
54 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Euro Amazon IPv6 JsDelivr Cloudflare JS CDN JS
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Erik Paulsson
Erik Paulsson investment in Venture Round - Camurus
Martin Gren
Martin Gren investment in Venture Round - Camurus
Official Site Inspections
http://www.camurus.com Semrush global rank: 7.41 M Semrush visits lastest month: 507
- Host name: 52.174.176.76
- IP address: 52.174.176.76
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Camurus"
Camurus - Org Chart, Teams, Culture & Jobs - The Org
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. …See details»
Camurus - Wikipedia
Camurus AB (publ) is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. See details»
Camurus – International pharmaceutical …
Mar 3, 2025 Camurus’ innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of …See details»
Camurus - Crunchbase Company Profile & Funding
Camurus may be growing as indicated by the positive sentiment from investors regarding the company's prospects. The company has reported strong earnings, which suggests robust …See details»
Camurus Company Profile | Management and Employees List
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and …See details»
Camurus appoints Behshad Sheldon as President of Camurus Inc.
Feb 13, 2024 In parallel, Camurus is building up an own commercial organization in the US to be ready for a planned launch of Oclaiz™ in the beginning of 2025. For more information Fredrik …See details»
Camurus’ Full Year Report 2024
Feb 13, 2025 [email protected]. Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 [email protected]. About Camurus Camurus is an …See details»
Polly Kingsmill - Head Of Marketing at Camurus - The Org
Before joining Camurus, they were a Senior Brand Manager - CNS at Teva Pharmaceuticals from May 2018 to April 2021. Polly also has experience at MENARINI Group, where they held roles …See details»
Jon U Garay Alonso - Chief Financial Officer at Camurus - The Org
Jon U is currently serving as the Chief Financial Officer at Camurus since February 2022. Prior to this, they held various positions at Baxter International Inc., including Europe Finance Director …See details»
Camurus to progress commercialization of Buvidal and advance …
Lund, Sweden — 6 February 2019 — The Board of Directors of Camurus AB (publ) (“Camurus” or the “Company”) (Nasdaq Stockholm, CAMX) has resolved on a new share issue of …See details»
CAMURUS | Medipha Santé
CAMURUS est une société pharmaceutique suédoise qui développe et commercialise des médicaments pour le traitement de maladies graves et chroniques, notamment la dépendance …See details»
Full year report 2016 - Camurus
The final quarter of 2016 saw us achieve a major milestone for Camurus. Results from our completed Phase 3 study of CAM2038 in opioid dependence demonstrated significantly better …See details»
Camurus - Crunchbase
Companies like Camurus include Fagron SA, PIQUR Therapeutics, and Acceleron Pharma. Fagron SA . Rotterdam, Zuid-Holland, The Netherlands 151 Contacts 1001-5000 employees . …See details»
Organization: Camurus LEI 5493003S6Z6VI7WYFQ06 - Cbonds.com
Camurus. Information about the issuer. News and credit ratings. (LEI 5493003S6Z6VI7WYFQ06). Tables with accounting and financial reporting.See details»
Fredrik Tiberg | Camurus | Sweden - OMICS International
Camurus Sweden. Biography. Fredrik Tiberg is President & Chief Executive Officer since 2003. Board Member since 2002.Born in 1963. His educational qualifications are M.Sc. in chemical …See details»
CAMRF | Camurus AB Financial Statements - WSJ
Camurus AB balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View CAMRF financial statements in full.See details»
Opioid dependence: buprenorphine prolonged-release injection
Buprenorphine prolonged-release injection (Buvidal, Camurus) is an opioid partial agonist/ antagonist. It is administered as a weekly or monthly subcutaneous injection and must be …See details»
Camurus uppdaterar kring den regulatoriska processen för …
Lund — 22 oktober 2024 — Camurus (NASDAQ STO: CAMX) meddelar idag att den amerikanska läkemedelsmyndigheten (FDA) utfärdat en begäran om ytterligare information, …See details»
Camurus spår miljardresultat 2025 - Dagens industri
Feb 13, 2025 Specialistläkemedelsbolaget Camurus räknar med att göra en vinst på uppemot 1,2 miljarder kronor under 2025. Det framgår av bokslutet, där siffrorna i övrigt är i linje med …See details»
Camurus AB Osakkeiden tekninen analyysi (CAMX)
Hae lyhyt katsaus - vahva osta, osta, vahva myy, myy tai neutraali -signaalit Camurus AB -osakkeelle. Tarkastele yksityiskohtaista teknistä analyysia, joka perustuu liukuvien …See details»